Skip to main content
Premium Trial:

Request an Annual Quote

Eppendorf Licenses Thermal Gradient Tech to Peqlab


Eppendorf said today that it has licensed patents covering gradient technology for thermal cyclers to Peqlab Biotechnologie.

The license includes US Patent No. 6,767,512, entitled "Temperature-regulating block with temperature-regulating devices;" and No. 7.074,367, entitled "Thermostated block with heat-regulating devices."

Hamburg, Germany-based Eppendorf uses the technology in its Eppendorf Mastercycler Pro Gradient, Mastercycler Nexus Gradient, and Mastercycler EP Realplex models; but has also licensed the technology to a slew of other life science companies for use in their thermal cyclers. These licnesees include Agilent, Roche, Takara Bio, Analytik Jena, Bulldog Bio, Labnet, and Bibby Scientific.

Peqlab, based in Erlangen, Germany, manufactures and distributes instruments, reagents, and consumables for life science researchers. Its products include the Primus Thermocycler for personal, benchtop applications; and the peqSTAR family of thermocyclers for higher throughput PCR using interchangeable well blocks.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.